Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Acro Biomedical (ACBM) EBT (2016 - 2025)

Acro Biomedical (ACBM) has 10 years of EBT data on record, last reported at $42526.0 in Q4 2025.

  • For Q4 2025, EBT rose 498.44% year-over-year to $42526.0; the TTM value through Dec 2025 reached -$101146.0, down 139.13%, while the annual FY2025 figure was -$101146.0, 139.13% down from the prior year.
  • EBT reached $42526.0 in Q4 2025 per ACBM's latest filing, up from -$117809.0 in the prior quarter.
  • Across five years, EBT topped out at $2.2 million in Q4 2021 and bottomed at -$4.0 million in Q3 2022.
  • Average EBT over 5 years is -$1.3 million, with a median of -$88651.5 recorded in 2021.
  • Peak YoY movement for EBT: soared 2885.05% in 2021, then plummeted 6503.69% in 2022.
  • A 5-year view of EBT shows it stood at $2.2 million in 2021, then plummeted by 276.9% to -$3.9 million in 2022, then surged by 99.54% to -$18240.0 in 2023, then skyrocketed by 41.49% to -$10673.0 in 2024, then skyrocketed by 498.44% to $42526.0 in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were $42526.0 in Q4 2025, -$117809.0 in Q3 2025, and -$15562.0 in Q2 2025.